Second Opinion: Investigators Provide Perspectives on the Current and Future Management of Small Cell Lung Cancer

Faculty

Faculty

Anne Chiang

MD, PhD

Yale University School of Medicine, New Haven, Connecticut

Associate Professor

Smilow Cancer Hospital, New Haven, Connecticut

Deputy Chief Medical Officer, Chief Integration Officer

Faculty

Luis Paz-Ares

MD, PhD

Hospital Universitario 12 de Octubre, Madrid, Spain

Chair of the Medical Oncology Department

Universidad Complutense, Madrid, Spain

Professor of Medicine

National Oncology Research Center, Madrid, Spain

Head of the Lung Cancer Unit

Moderator

Misty Dawn Shields

MD, PhD

Indiana University School of Medicine, Indianapolis, Indiana

Assistant Professor of Clinical Medicine

Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana

Adjunct Assistant Professor of Medical and Molecular Genetics, Associate Member, Experimental and Developmental Therapeutics, Department of Medicine, Division of Hematology/Oncology, Thoracic Oncology

Additional faculty to be announced.

Program Schedule — Central Time
6:30 PM – 7:00 PM — Registration and Dinner
7:00 PM – 9:00 PM — Educational Meeting

MODULE 1: Optimizing First-Line and Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

• Long-term outcomes with durvalumab and atezolizumab, respectively, in combination with platinum-based chemotherapy as first-line treatment for patients with ES-SCLC
• Appropriate integration of first-line atezolizumab/carboplatin/etoposide and durvalumab/platinum/etoposide into current ES-SCLC management
• Rationale for the design of the Phase III IMforte trial evaluating lurbinectedin with atezolizumab versus atezolizumab alone as maintenance therapy after induction atezolizumab/carboplatin/etoposide for patients with ES-SCLC
• Published efficacy and safety findings with the addition of lurbinectedin to maintenance atezolizumab in the IMforte trial
• Recent FDA approval of lurbinectedin in combination with atezolizumab as maintenance treatment for ES-SCLC after first-line induction therapy with atezolizumab/carboplatin/etoposide; appropriate selection of patients for this strategy
• Other ongoing research studies evaluating novel first-line and maintenance strategies

MODULE 2: Management of Relapsed/Refractory (R/R) SCLC

• Factors in the selection and sequencing of therapy for R/R SCLC
• Available research findings with and current clinical role of lurbinectedin for patients with SCLC that has progressed after platinum-based therapy
• Scientific rationale for targeting delta-like ligand 3 (DLL3) in SCLC; mechanism of action of the DLL3 x CD3 bispecific T-cell engagers tarlatamab and obrixtamig
• Key efficacy and safety findings from the Phase III DeLLphi-304 study of tarlatamab for previously treated SCLC; FDA approval and current clinical role
• Safety profile of tarlatamab, including rates and severity of cytokine release syndrome and neurotoxicity/ICANS (immune effector cell-associated neurotoxicity syndrome); appropriate monitoring, mitigation and management of adverse events
• Structural and mechanistic similarities and differences between tarlatamab and obrixtamig
• Early data with and ongoing evaluation of obrixtamig for patients with R/R SCLC

MODULE 3: Ongoing Investigation and Potential Role of Antibody-Drug Conjugates for SCLC

• Rationale for targeting B7-H3 in SCLC; mechanism of action of the B7-H3-directed antibody-drug conjugate ifinatamab deruxtecan (I-DXd)
• Clinical outcomes observed with I-DXd among patients with recurrent ES-SCLC in the Phase II Ideate-Lung 01 trial
• Ongoing studies, such as IDeate-Lung02 and IDeate-Lung03, evaluating I-DXd alone and in combination with other systemic therapies for ES-SCLC; potential clinical role
• Published efficacy and safety data with sacituzumab govitecan as second-line therapy for ES-SCLC
• FDA breakthrough therapy designation for sacituzumab govitecan for patients with ES-SCLC whose disease has progressed on or after platinum-based chemotherapy; potential clinical role in this setting
• Design, eligibility criteria and primary and secondary endpoints of the Phase III EVOKE-SCLC-04 study evaluating sacituzumab govitecan versus chemotherapy for previously treated ES-SCLC; estimated completion date
• Other novel antibody-drug conjugates under investigation for ES-SCLC

MODULE 4: Management of Limited-Stage SCLC (LS-SCLC)

• Long-term outcomes achieved with historical treatment approaches for LS-SCLC; rationale for the investigation of immune checkpoint inhibition
• Major efficacy findings from the Phase III ADRIATIC trial assessing durvalumab as consolidation treatment for patients with LS-SCLC after completion of chemoradiation therapy (CRT)
• Tolerability profile documented with consolidation durvalumab in the ADRIATIC trial
• FDA approval and current clinical role of durvalumab consolidation for LS-SCLC
• Ongoing Phase IIIb ALBORAN study evaluating durvalumab after CRT in a real-world population of patients with LS-SCLC
• Design, eligibility criteria and primary and secondary endpoints of the Phase III DeLLphi-306 study evaluating tarlatamab after CRT for LS-SCLC; estimated completion date

Target Audience
This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of lung cancer.

Learning Objectives
Upon completion of this activity, participants should be able to 

• Appraise available findings from clinical studies investigating anti-PD-1/PD-L1 antibody consolidation therapy for patients with limited-stage small cell lung cancer (SCLC) who have not experienced disease progression after standard platinum-based chemotherapy concurrent with radiation therapy, and determine the clinical role of this approach.
• Review long-term data supporting the use of anti-PD-1/PD-L1 antibodies in combination with platinum-based chemotherapy as first-line therapy for patients with extensive-stage SCLC, and consider how these regimens can be appropriately and safely integrated into clinical practice.
• Appreciate the biological rationale for the evaluation of maintenance treatment after chemoimmunotherapy induction, and assess available research findings with and the current role of this approach.
• Evaluate available clinical trial findings with FDA-approved agents for patients with SCLC who experience disease progression on or after platinum-containing first-line therapy, and determine how to optimally integrate these therapies into current treatment algorithms.
• Interrogate published clinical trial data with DLL3-directed T-cell engager therapy for SCLC, and identify patients with relapsed/refractory (R/R) disease appropriate for this novel approach.
• Appreciate the incidence of B7-H3 overexpression in patients with SCLC, and develop an understanding of the rationale for, available data with and ongoing studies of B7-H3-directed antibody-drug conjugates for R/R disease.
• Reflect on the biological rationale for the evaluation of TROP2-directed antibody-drug conjugates for SCLC, and consider available research findings and ongoing studies with these agents.
• Assess ongoing clinical research studies evaluating novel agents and treatment strategies under development for the management of patients with SCLC, and counsel patients regarding the potential benefits of trial participation.

CME Credit Form
A CME credit link will be given to each participant as part of the meeting course materials.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided.

FACULTY
To be announced.

MODERATOR
To be announced.

EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Summit Therapeutics, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from Amgen Inc, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Gilead Sciences Inc, Jazz Pharmaceuticals Inc, and Merck.

Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Phone: (312) 922-4400

Meeting Room
Continental Room A (Lobby Level)

Directions
The Hilton Chicago hotel is located just 5 minutes (2.5 miles) north of the McCormick Place convention center, where the ASCO Annual Meeting is taking place.